Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Cancer cell or component thereof
Reexamination Certificate
2008-01-16
2010-10-05
Canella, Karen A (Department: 1643)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Cancer cell or component thereof
C435S374000
Reexamination Certificate
active
07807186
ABSTRACT:
The present invention relates to tumor cell-based vaccines and methods of using same, wherein the vaccines are based on naturally immune privileged tumor cells that have been genetically modified to express MHC-II restricted peptides derived from endogenously encoded tumor antigens, activate CD4+ T-lymphocytes, provide an array of antigens to which the host is not tolerized and/or induce immunity against the originating tumor cells as well as against metastatic tumor cells.
REFERENCES:
patent: 5858776 (1999-01-01), Ostrand-Rosenberg et al.
patent: 6149905 (2000-11-01), Ostrand-Rosenberg et al.
patent: 6319709 (2001-11-01), Ostrand-Rosenberg et al.
patent: 2002/0086421 (2002-07-01), Ostrand-Rosenberg et al.
patent: 2003/0124103 (2003-07-01), Ostrand-Rosenberg et al.
patent: 2006/0099195 (2006-05-01), Ostrand-Rosenberg et al.
Chen et al (Experimental Eye Research, Apr. 2006).
Leach et al (Journal of Immunology, 1995, vol. 154, pp. 738-743).
Abstract of Chen et al (Invest Ophthalmol Vis Sci, 2003, vol. 44, E-abstract 765).
Abstract of Wheeler, Salud d'publica de M'exico, 1997 Jul.-Aug., 39(4):283-287).
Stedman's Medical Dictionary, 27thEdition, 2000, Definition for “Vaccine”.
Efferson (Anticancer Research, 2005, vol. 25, pp. 715-724).
Bachmann et al (Journal of Immunology, 2005, vol. 175, pp. 4677-4685).
Streilein et al (Journal of Immunology, 1997, vol. 158, pp. 3557-3560).
Roitt et al, Ed.s, “Immunology” (textbook), 5thEdition, pp. 91-92 and 141.
Ksander and Streinlein (Chemical Immunology, 1994, vol. 58, pp. 117-145).
Albert DM, Niffenegger AS, Willson JK. Treatment of metastatic uveal melanoma: review and recommendations.Surv Ophthalmol1992;36:429-38.
Harbour J. Clinical overview of uveal melanoma: introduction to tumors of the eye. In: Albert DM, Polans A, editors.Ocular Oncology.Marcel Dekker; 2003.
Staveley-O'Carroll K, Sotomayor E, Montgomery J, et al. Induction of antigen-specific T cell anergy: an early event in the course of tumor progression.Proc Natl Acad Sci U S A1998;95:1178-83.
Niederkorn JY. See no evil, hear no evil, do no evil: the lessons of immune privilege.Nat Immunol2006;7:354-9.
Streilein JW. Ocular immune privilege: therapeutic opportunities from an experiment of nature.Nat Rev Immunol2003;3:879-89.
Wang JC, Livingstone AM. Cutting edge: CD4+ T cell help can be essential for primary CD8+ T cell responses in vivo.J Immunol2003;171:6339-43.
Kern DE, Klarnet JP, Jensen MC, Greenberg PD. Requirement for recognition of class II molecules and processed tumor antigen for optimal generation of syngeneic tumor-specific class I-restricted CTL.J Immunol1986;136:4303-10.
Ossendorp F, Mengede E, Camps M, Filius R, Melief CJ. Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors.J Exp Med1998;187:693-702.
Ostrand-Rosenberg S, Thakur A, Clements V. Rejection of mouse sarcoma cells after transfection of MHC class II genes.J Immunol1990;144:4068-71.
Bennett SR, Carbone FR, Karamalis F, Miller JF, Heath WR. Induction of a CD8+ cytotoxic T lymphocyte response by cross-priming requires cognate CD4+ T cell help.J Exp Med1997;186:65-70.
Keene JA, Forman J. Helper activity is required for the in vivo generation of cytotoxic T lymphocytes.J Exp Med1982;155:768-82.
Bennett SR, Carbone FR, Karamalis F, Flavell RA, Miller JF, Heath WR. Help for cytotoxic-T-cell responses is mediated by CD40 signalling.Nature1998;393:478-80.
Ridge JP, Di Rosa F, Matzinger P. A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell.Nature1998;393:474-8.
Schoenberger SP, Toes RE, van der Voort EI, Offringa R, Melief CJ. T-cell help for cytotoxic T lymphocytes is mediated by CD40-40L interactions.Nature1998;393:480-3.
Shedlock DJ, Shen H. Requirement for CD4 T cell help in generating functional CD8 T cell memory.Science2003;300:337-9.
Janssen EM, Lemmens EE, Wolfe T, Christen U, von Herrath MG, Schoenberger SP. CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes.Nature2003;421:852-6.
Grakoui A, Shoukry NH, Woollard DJ, et al. HCV persistence and immune evasion in the absence of memory T cell help.Science2003;302:659-62.
Sun JC, Bevan MJ. Defective CD8 T cell memory following acute infection without CD4 T cell help.Science2003;300:339-42.
Mooy CM, De Jong PT. Prognostic parameters in uveal melanoma: a review.Surv Ophthalmol1996;41:215-28.
Peters S, Voelter V, Zografos L, et al. Intra-arterial hepatic fotemustine for the treatment of liver metastases from uveal melanoma: experience in 101 patients.Ann Oncol2006;17:578-83.
Noter SL, Rothbarth J, Pijl ME, et al. Isolated hepatic perfusion with high-dose melphalan for the treatment of uveal melanoma metastases confined to the liver.Melanoma Res2004;14:67-72.
Onken MD, Worley LA, Ehlers JP, Harbour JW. Gene expression profiling in uveal melanoma reveals two molecular classes and predicts metastatic death.Cancer Res2004;64:7205-9.
Tschentscher F, Husing J, Holter T, et al. Tumor classification based on gene expression profiling shows that uveal melanomas with and without monosomy 3 represent two distinct entities.Cancer Res2003;63:2578-84.
Svane IM, Engel AM, Nielsen MB, Ljunggren HG, Rygaard J, Werdelin O. Chemically induced sarcomas from nude mice are more immunogenic than similar sarcomas from congenic normal mice.Eur J Immunol1996;26:1844-50.
Shankaran V, Ikeda H, Bruce AT, et al. IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001;410:1107-11.
Danna EA, Sinha P, Gilbert M, Clements VK, Pulaski BA, Ostrand-Rosenberg S. Surgical removal of primary tumor reverses tumor-induced immunosuppression despite the presence of metastatic disease.Cancer Res2004;64:2205-11.
Maat W, Haasnoot GW, Class FH, Schalij-Delfos NE, Schreuder GM, Jager MJ. HLA Class I and II genotype in uveal melanoma: relation to occurrence and prognosis. InvestOphthalmol Vis Sci2006;47:3-6.
Kan-Mitchell J, Liggett PE, Harel W, et al. Lymphocytes cytotoxic to uveal and skin melanoma cells from peripheral blood of ocular melanoma patients.Cancer Immunol Immunother1991;33:333-40.
van Dinten LC, Pul N, van Nieuwpoort AF, Out CJ, Jager MJ, van den Elsen PJ. Uveal and cutaneous melanoma: shared expression characteristics of melanoma-associated antigens.Invest Ophthalmol Vis Sci2005;46:24-30.
Nabel GJ, Gordon D, Bishop DK, et al. Immune response in human melanoma after transfer of an allogeneic class I major histocompatibility complex gene with DNA-liposome complexes.Proc Natl Acad Sci U S A1996;93:15388-93.
Chen PW, Murray TG, Salgaller ML, Ksander BR. Expression of MAGE genes in ocular melanoma cell lines.J Immunother1997;20:265-75.
Radosevich M, Jager M, Ono SJ. Inhibition of MHC class II gene expression in uveal melanoma cells is due to methylation of the CIITA gene or an upstream activator.Exp Mol Pathol2007;82:68-76.
Chang CH, Flavell RA. Class II transactivator regulates the expression of multiple genes involved in antigen presentation.J Exp Med1995;181:765-7.
Sotiriadou R, Perez SA, Gritzapis AD, et al. Peptide HER2(776-788) represents a naturally processed broad MHC class II-restricted T cell epitope.Br J Cancer2001;85:1527-34.
Salazar LG, Fikes J, Southwood S, et al. Immunization of cancer patients with HER-2
eu-derived peptides demonstrating high-affinity binding to multiple class II alleles.Clin Cancer Res2003;9:5559-65.
Thompson JA, Dissanayake SK, Ksander BR, Knutson KL, Disis ML, Ostrand-Rosenberg S. Tumor cells transduced with the MHC class II transactivator and CD80 activate tumor-specific CD4+ T cells whether or not they are silenced for invariant chain.Cancer Res2006;66:1147-54.
Dissanayake SK, Thompson JA, Bosch JJ, et al. Activation of tumor-specific CD4(+) T lymphocytes by major histocompatibility complex class II tumor cell vaccines: a novel cell-based immunotherapy.Cancer Res2004;64:1867-74.
Verbik DJ, Murray TG, Tran JM, Ksander BR. Melanomas that develop within the eye inhibit lymphocyte proliferation.Int J Cancer1997;73:470-
Bosch Jacobus J.
Ksander Bruce R.
Ostrand-Rosenberg Suzanne
Canella Karen A
Fuierer Marianne
Moore & Van Allen PLLC
University of Maryland Baltimore County
LandOfFree
Tumor cells from immune privileged sites as base cells for... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Tumor cells from immune privileged sites as base cells for..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tumor cells from immune privileged sites as base cells for... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4201902